Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05093504 · ClinicalTrials.gov registry record · NA
Safe and Timely Antithrombotic Removal - Direct Oral Anticoagulants Apixaban & Rivaroxaban (STAR-D)
A NA study, sponsored by CytoSorbents.
- Terminated
- Registry status
- NA
- Development phase
- 9
- Enrollment target
NCT05093504 is a NA study that was terminated before completion, run by CytoSorbents. The registered enrollment target is 9 participants.
The verdict
NCT05093504, a NA study, was terminated before completion, sponsored by CytoSorbents.
- TERMINATED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
Study Summary
Prospective, Multicenter, Double-blind, Randomized, Study to Evaluate DrugSorb-ATR Removal of Apixaban and Rivaroxaban to Reduce Likelihood of Serious Bleeding in Patients Undergoing Urgent Cardiothoracic Surgery
Interventions
- DEVICE Sham comparator
- DEVICE DrugSorb-ATR system
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2021-12-27 |
| Est. Completion | 2024-01-29 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05093504
The ClinicalTrials.gov registry entry for NCT05093504 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CytoSorbents, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sham comparator is the first listed.
NCT05093504 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05093504 about?
NCT05093504 is a clinical study titled "Safe and Timely Antithrombotic Removal - Direct Oral Anticoagulants Apixaban & Rivaroxaban (STAR-D)". Prospective, Multicenter, Double-blind, Randomized, Study to Evaluate DrugSorb-ATR Removal of Apixaban and Rivaroxaban to Reduce Likelihood of Serious Bleeding in Patients Undergoing Urgent Cardiothoracic Surgery
What is the current status of trial NCT05093504?
This trial is currently terminated. It is a NA study. The enrollment target is 9 participants. The study started on 2021-12-27. Estimated completion is 2024-01-29.
What interventions are being tested in trial NCT05093504?
The interventions under investigation include: Sham comparator (DEVICE), DrugSorb-ATR system (DEVICE).
Who is sponsoring clinical trial NCT05093504?
This trial is sponsored by CytoSorbents, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.